论文部分内容阅读
目的观察冻干重组人脑利纳肽在急诊治疗急性心力衰竭的临床疗效。方法 96例急性心力衰竭患者随机分为新活素组48例和对照组48例,两组患者均给予标准的抗心力衰竭治疗。新活素组加用冻干重组人脑利纳肽,首次负荷剂量为1.5μg/kg,静脉注射,然后按0.01μg/(kg.min)剂量持续静脉泵入,连续用药48小时,观察患者治疗前和治疗后48小时的临床症状、心率、血压及左室射血分数(LVEF)等情况,测定血浆中N-末端脑利纳肽前体(NT-proBNP)的浓度。结果新活素组的显效率和总有效率均显著优于对照组(P<0.01)。两组治疗后48小时心率、血压及左室射血分数、血浆NT-proBNP浓度均较治疗前明显改善(P<0.05)。新活素组治疗后48小时各项指标的变化较对照组改善得更加显著(P<0.05),特别是NT-proBNP浓度的改变。结论冻干重组人脑利纳肽可以显著改善急性心力衰竭患者的临床症状和心功能,降低血浆中NT-proBNP浓度。
Objective To observe the clinical efficacy of lyophilized recombinant human brain linacide in emergency treatment of acute heart failure. Methods Ninety-six patients with acute heart failure were randomly divided into 48 new cases and 48 normal controls. Both groups were given standard anti-heart failure treatment. The new active group plus freeze-dried recombinant human brain Linanide, the first load dose of 1.5μg / kg, intravenous injection, and then by 0.01μg / (kg.min) dose continuous intravenous infusion of 48 hours of continuous observation patients Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured before treatment and at 48 hours after treatment for clinical symptoms, heart rate, blood pressure, and left ventricular ejection fraction (LVEF) Results The apparent efficiency and total effective rate of the new active group were significantly better than the control group (P <0.01). Heart rate, blood pressure, left ventricular ejection fraction and plasma NT-proBNP concentration in both groups were significantly improved 48h after treatment (P <0.05). The changes of each index of the new activin group 48 hours after treatment were more significantly improved than the control group (P <0.05), especially NT-proBNP concentration changes. Conclusion The freeze-dried recombinant human brain linarin peptide can significantly improve the clinical symptoms and cardiac function in patients with acute heart failure and reduce the concentration of NT-proBNP in plasma.